Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Melanin-Concentrating Hormone Receptor 1 (G-Protein Coupled Receptor 24 or MCH-1R or Somatostatin Receptor-Like Protein or MCHR1 or GPR24 or SLC1) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Melanin-Concentrating Hormone Receptor 1, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanin-Concentrating Hormone Receptor 1 and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Melanin-Concentrating Hormone Receptor 1 Overview
  3. Therapeutics Development
  4. Pipeline Products for Melanin-Concentrating Hormone Receptor 1 - Overview
  5. Pipeline Products for Melanin-Concentrating Hormone Receptor 1 - Comparative Analysis
  6. Melanin-Concentrating Hormone Receptor 1 - Therapeutics under Development by Companies
  7. Melanin-Concentrating Hormone Receptor 1 - Therapeutics under Investigation by Universities/Institutes
  8. Melanin-Concentrating Hormone Receptor 1 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Melanin-Concentrating Hormone Receptor 1 - Products under Development by Companies
  13. Melanin-Concentrating Hormone Receptor 1 - Products under Investigation by Universities/Institutes
  14. Melanin-Concentrating Hormone Receptor 1 - Companies Involved in Therapeutics Development
  • Albany Molecular Research, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • LEO Pharma A/S

For more information visit http://www.researchandmarkets.com/research/d3n3f5/melaninconcentrat

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs, Proteomics, Endocrine and Metabolic Disorder Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs, Proteomics, Endocrine and Metabolic Disorder Drugs